Pelthos Therapeutics Inc. 8-K

What Happened
Pelthos Therapeutics Inc. announced (Item 1.01) that it entered into an Asset Purchase Agreement with Hatchtech Pty Ltd to acquire all rights and assets related to the Xeglyze product (Abametapir formulation for head lice). The company previously paid a $450,000 down payment on November 20, 2025 and paid the remaining $1,350,000 on December 23, 2025, for an aggregate purchase price of $1,800,000. Pelthos has contractual claw-back rights (up to 100% of the purchase price) for certain Hatchtech defaults and if closing had not occurred by the specified closing deadline. Pelthos will issue a press release on January 5, 2026 announcing the closing.

Key Details

• Purchase price: $1,800,000 total (Down Payment $450,000; additional cash $1,350,000).
• Assets acquired include the Xeglyze product, related patents/trademarks, regulatory materials, product know-how, inventory, equipment and other tangible and intangible assets.
• Claw-back: Pelthos may recover up to 100% of the purchase price for certain seller defaults and if the transaction did not close by the contract deadline.
• Press release: Scheduled for January 5, 2026; related agreements filed as Exhibits (with confidential portions redacted).

Why It Matters
This is an acquisition (Item 1.01) that gives Pelthos ownership of a marketed head-lice product and the associated intellectual property, regulatory approvals and inventory for a modest cash outlay. For investors, the deal is a concrete revenue/portfolio expansion move — Pelthos has acquired an existing product rather than developing one from scratch, which may shorten time to market activity or sales related to Xeglyze. The claw-back protections reduce Pelthos’s deal risk if Hatchtech fails to meet certain obligations.